Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02831569 | Japanese IP-TN Trial | PHASE3 | COMPLETED | 80 | — | — | Jul 27, 2016 | Oct 19, 2016 | Jul 20, 2018 | 3 | Japan |
The outcome measure presents percentage of patients with drug-related AEs.
| Arm | Type | Description |
|---|---|---|
| Loxoprofen sodium/methocarbamol FDC | EXPERIMENTAL | fixed dose combination (FDC) tablets |
| Name | Type | Description |
|---|---|---|
| Loxoprofen sodium | DRUG | - |
| Methocarbamol | DRUG | - |
Inclusion criteria: * Male or female outpatients aged \>=15 years at the time of giving consent. * Patients diagnosed with low back pain, scapulohumeral periarthritis, or cervico-omo-brachial syndrome prior to giving consent. Patients with cervico-omo-brachial syndrome must have the associated symp...